CBD shows strong anti-inflammatory effects in animal MS models but clinical evidence is still limited

Rodent EAE models strongly support CBD as effective against autoimmune neuroinflammation. However, clinical evidence in actual MS patients is limited and usually negative. The review argues this disconnect may be due to too few clinical studies and the use of suboptimal dosing regimens in humans.

Systematic review of CBD's immunomodulatory effects in EAE (experimental autoimmune encephalomyelitis, the standard MS animal model) and in MS clinical studies. Retrieved and critically evaluated available evidence for immune and disease-modifying effects.

MS patients frequently use cannabis products, and CBD's anti-inflammatory properties make it a theoretical candidate for disease modification. Understanding why animal success has not translated to clinical benefit is essential for designing effective trials.

The gap between robust animal evidence and disappointing clinical results is common in drug development but especially relevant for CBD, where regulatory and cultural barriers have limited the ability to test adequate doses in well-designed human trials.

Systematic review limited by the paucity of clinical studies available. EAE is an imperfect model of human MS. Cannot determine optimal human dosing from animal data alone. Publication bias may affect both animal and clinical literature.